1. Home
  2. EYPT vs TCPC Comparison

EYPT vs TCPC Comparison

Compare EYPT & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYPT
  • TCPC
  • Stock Information
  • Founded
  • EYPT 1987
  • TCPC 2006
  • Country
  • EYPT United States
  • TCPC United States
  • Employees
  • EYPT N/A
  • TCPC N/A
  • Industry
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • TCPC Finance/Investors Services
  • Sector
  • EYPT Industrials
  • TCPC Finance
  • Exchange
  • EYPT Nasdaq
  • TCPC Nasdaq
  • Market Cap
  • EYPT 579.4M
  • TCPC 665.8M
  • IPO Year
  • EYPT 2005
  • TCPC 2012
  • Fundamental
  • Price
  • EYPT $9.55
  • TCPC $7.77
  • Analyst Decision
  • EYPT Strong Buy
  • TCPC Hold
  • Analyst Count
  • EYPT 8
  • TCPC 4
  • Target Price
  • EYPT $24.75
  • TCPC $7.50
  • AVG Volume (30 Days)
  • EYPT 841.7K
  • TCPC 518.6K
  • Earning Date
  • EYPT 08-06-2025
  • TCPC 08-06-2025
  • Dividend Yield
  • EYPT N/A
  • TCPC 15.21%
  • EPS Growth
  • EYPT N/A
  • TCPC N/A
  • EPS
  • EYPT N/A
  • TCPC N/A
  • Revenue
  • EYPT $56,042,000.00
  • TCPC $259,596,996.00
  • Revenue This Year
  • EYPT N/A
  • TCPC N/A
  • Revenue Next Year
  • EYPT N/A
  • TCPC N/A
  • P/E Ratio
  • EYPT N/A
  • TCPC N/A
  • Revenue Growth
  • EYPT 12.04
  • TCPC 20.88
  • 52 Week Low
  • EYPT $3.91
  • TCPC $6.27
  • 52 Week High
  • EYPT $13.99
  • TCPC $11.06
  • Technical
  • Relative Strength Index (RSI)
  • EYPT 61.03
  • TCPC 54.15
  • Support Level
  • EYPT $7.94
  • TCPC $7.40
  • Resistance Level
  • EYPT $10.77
  • TCPC $7.78
  • Average True Range (ATR)
  • EYPT 0.76
  • TCPC 0.17
  • MACD
  • EYPT -0.01
  • TCPC -0.01
  • Stochastic Oscillator
  • EYPT 56.89
  • TCPC 63.16

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

About TCPC BlackRock TCP Capital Corp.

BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.

Share on Social Networks: